GlassScriptPhysician profile
Mark G Hebert
NPI 1831268630
$15,001.40
in general payments reported to CMS, 2019-2025
21 companies · $1,002 in 2025
The $1,002 reported for 2025 was more than what 85% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $842 · 2022: $3,328 · 2023: $5,876 · 2024: $3,953 · 2025: $1,002.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $5,475 · Food and Beverage: $4,622 · Travel and Lodging: $734.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $5,475.00 |
| Food and Beverage | $4,622.30 |
| Travel and Lodging | $733.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $11,889.50 | 2021-2025 | Dovato, Cabenuva, Apretude |
| Gilead Sciences, INC. | $1,236.28 | 2021-2025 | Biktarvy |
| Merck Sharp & Dohme LLC | $565.90 | 2021-2025 | Pifeltro, Delstrigo, Dificid |
| Abbvie INC. | $251.44 | 2021-2024 | |
| Theratechnologies INC. | $242.55 | 2021-2025 | Egrifta, Trogarzo |
| Emd Serono, INC. | $218.82 | 2021-2024 | Serostim |
| Janssen Biotech, INC. | $175.86 | 2021-2023 | Symtuza |
| Novo Nordisk INC | $94.94 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Verity Pharmaceuticals INC. | $47.77 | 2025 | Tlando |
| Napo Pharmaceuticals INC | $37.53 | 2024-2025 | Mytesi |
| Lilly USA, LLC | $36.50 | 2023-2024 | Mounjaro, Jardiance, Zepbound |
| Exact Sciences Corporation | $30.35 | 2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Otsuka America Pharmaceutical, INC. | $29.51 | 2024 | Rexulti |
| Abbott Laboratories | $22.05 | 2025 | Freestyle Libre 3 |
| Takeda Pharmaceuticals U.S.A., INC. | $19.86 | 2024 | Trintellix |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $19.17 | 2023 | Shingrix, Arexvy |
| Halozyme INC | $17.98 | 2023 | |
| Antares Pharma, INC. | $17.87 | 2022 | |
| Pfizer INC. | $16.35 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $15.66 | 2023 | |
| Dexcom, INC. | $15.51 | 2023 | Dexcom G6 Transmitter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Hebert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.